Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Net Income: 2013-2024

Historic Net Income for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$269.9 million.

  • Viridian Therapeutics, Inc.\DE's Net Income rose 54.18% to -$35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$302.5 million, marking a year-over-year decrease of 17.75%. This contributed to the annual value of -$269.9 million for FY2024, which is 13.55% down from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Net Income is -$269.9 million, which was down 13.55% from -$237.7 million recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Net Income ranged from a high of -$79.4 million in FY2021 and a low of -$269.9 million during FY2024.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Net Income value was -$237.7 million (recorded in 2023), while the average stood at -$212.5 million.
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 159.00% in 2020, then climbed by 28.38% in 2021.
  • Viridian Therapeutics, Inc.\DE's Net Income (Yearly) stood at -$110.9 million in 2020, then increased by 28.38% to -$79.4 million in 2021, then slumped by 63.54% to -$129.9 million in 2022, then slumped by 83.05% to -$237.7 million in 2023, then declined by 13.55% to -$269.9 million in 2024.